| Trial ID: | L3941 |
| Source ID: | NCT01424046
|
| Associated Drug: |
Basal Insulin Glargine
|
| Title: |
Health Care for Type 1 Diabetes in Developing World
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes
|
| Interventions: |
DRUG: basal insulin glargine|DRUG: standard therapy
|
| Outcome Measures: |
Primary: HbA1c, The primary outcome is the level of blood sugar control after 1 years treatment as determined by the Hb A1c test, one year | Secondary: Microalbuminuria, Microalbuminuria, the leakage of abnormal amounts of protein in the urine is a major complication of type 1 diabetes and the prevalence of this in the two groups is a secondary outcome, one year
|
| Sponsor/Collaborators: |
Sponsor: University of Pittsburgh | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National University, Rwanda|Association Rwandaise des Diabetiques
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
|
| Enrollment: |
50
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2011-05
|
| Completion Date: |
2014-11
|
| Results First Posted: |
|
| Last Update Posted: |
2014-12-05
|
| Locations: |
Association Rwandese des Diabetiques, Kigali, Kigali Provence, Rwanda
|
| URL: |
https://clinicaltrials.gov/show/NCT01424046
|
